Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Impax, Tolmar in Development and Supply Pact | Contract Pharma
Breaking News, Collaborations & Alliances

Impax, Tolmar in Development and Supply Pact

Will develop, supply and distribute alternative dosage form products

Impax Laboratories and Tolmar have entered a multi-product agreement for the development, supply and distribution of alternative dosage form products. The products and terms were not disclosed.

“We are excited to expand our relationship with Tolmar on these products. It represents an ideal extension of our initial product agreement,” said Larry Hsu, Ph.D., president and chief executive officer of Impax Laboratories. “In the past two years, we have entered into four distinct partnerships for alternative dosage form products as we continue to execute our strategy of diversifying our product base. Our business development activities will continue to focus on delivering growth from high-value products, technologies, and businesses in complementary dosage forms.”

Mike Duncan, chief executive officer of Tolmar, said, “We are very pleased with this agreement. Tolmar is once again recognized as a key player in the specialty pharma space. This agreement is aligned with our long-term corporate strategy and we firmly believe that Impax Laboratories is the right partner for these products. Tolmar is continuously expanding its facilities and employee base to meet current and future needs.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters